Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that its first ...

Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of ...

Innovent Biologics’ Sycume receives China NMPA approval for treatment of thyroid eye disease: San Francisco Monday, March 17, 2025, 16:00 Hrs [IST] Innovent Biologics, Inc, a wo ...

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

for the treatment of thyroid eye disease (TED). As China's first and the world's second approved IGF-1R antibody drug, SYCUME® has ended a 70-year drought of no new treatment option for TED in China.

Innovent Biologics (HKEX: 01801) has gained approval in China for Sycume (teprotumumab), the country’s first IGF-1R antibody for thyroid eye disease (TED). The National Medical Products Administration ...

("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and ...

Background: Dysthyroid optic neuropathy (DON), the most severe complication of thyroid eye disease (TED), has unclear mechanisms ... related molecules and immune cell infiltration in its pathogenesis.

Here are six possible triggers. More than one-third of people with Graves’ disease develop Graves’ ophthalmopathy, or thyroid eye disease. It happens when your immune system attacks the ...